Speciality chemical substances supplier Evonik has entered right into a provide settlement with the biotechnology firm Cassava Sciences.
By way of the settlement, Evonik will provide Cassava with large-scale, clinical-grade portions of simufilam, a drug candidate for the therapy of Alzheimer’s illness. Evonik will produce the drug candidate at its Tippecanoe website within the state of Indiana, USA.
“We’re delighted to be collaborating with Cassava and contributing to struggle Alzheimer’s collectively. We’re dedicated to supporting Cassava of their objectives to keep up the standard of life for tens of millions of sufferers around the globe and to additional advance potential therapy choices”, stated Thomas Riermeier, head of Evonik’s Well being Care enterprise line.
“I’m happy with our success to this point in being an efficient collaborator with Evonik, an organization with an extended, profitable and dependable observe report of supporting pharmaceutical provide chains,” stated Remi Barbier, president and CEO of Cassava Sciences.
“Evonik has a extremely versatile and agile strategy, which allows us to implement tailored options for biotechnology and pharmaceutical purchasers. Our world community contains extremely specialised services in Europe and the US with the capabilities required for all levels of drug manufacturing, from small portions for feasibility testing and medical trials, to large-scale, clinical-grade last merchandise,” stated Andreas Meudt, head of Evonik Well being Care’s Unique Synthesis enterprise.